---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-003444"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-09-30T23:59:59+00:00"
generated_at: "2026-05-17T05:19:12.813039+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Silexion reports SIL204 shows up to 99.7% inhibition across 11 human cell lines, first gastric cancer data

## Summary
- SIL204 achieved 83.5% to 99.7% inhibition at nanomolar concentrations (IC50 23.4–85.3 nM) in 11 lines from 5 cancer types.
- Highest activity: 99.7% inhibition in NCIH2009 lung cells (G12A mutation); first gastric cancer data showed 89.2% inhibition (G12D).
- Pancreatic G12R (17% of cases) showed 91.5% inhibition (IC50 31.5 nM) in KP2 cells; expanded colorectal validation in HCT 116 (G13D).
- SIL204 now confirmed active against G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations.
- Phase 2/3 trial planned H1 2026; regulatory submissions to Israel MoH in Q4 2025 and EU in Q1 2026.

## SEC filing metadata
- accession: 0001178913-25-003444
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325003444/0001178913-25-003444-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325003444/zk2533822.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-003444
- JSON: https://secwatch.observer/filing/0001178913-25-003444.json
- Plain text: https://secwatch.observer/filing/0001178913-25-003444.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.